Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Russell-Jones

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Diabetes, Obesity & Metabolism|June 3, 2017
Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK settingDavid Russell-Jones, Simon R Heller, Sarah Buchs, et al.
BJU International|September 22, 2011
A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapyJenny P Nobes, Stephen E M Langley, Tanya Klopper, et al.
Diabetes|January 31, 2006
Contrasting insulin sensitivity of endogenous glucose production rate in subjects with hepatocyte nuclear factor-1beta and -1alpha mutationsAnna Brackenridge, Ewan R Pearson, Fariba Shojaee-Moradie, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trialsBernard Zinman, J Hans DeVries, Bruce Bode, et al.
Diabetes, Obesity & Metabolism|January 10, 2018
Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trialChantal Mathieu, Bruce W Bode, Edward Franek, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|November 9, 2024
The practical operation and consequences of glucose measurement by pilots with diabetesKa Siu Fan, Antonios Manoli, Fariba Shojaee-Moradie, et al.
Diabetes, Obesity & Metabolism|October 7, 2021
Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trialMelanie J Davies, Julio Rosenstock, Amar Ali, et al.
Diabetes Care|January 3, 2012
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind studyDavid Russell-Jones, Robert M Cuddihy, Markolf Hanefeld, et al.
Advances in Therapy|August 25, 2011
Insulin therapy in diabetes and cancer risk: current understanding and implications for future study: proceedings from a meeting of a European Insulin Safety Consensus Panel, convened and sponsored by Novo Nordisk, held Tuesday October 5, 2010 at The Radisson Edwardian Heathrow Hotel, Hayes, Middlesex, UKStephen C L Gough, Cristóbal Belda-Iniesta, Christopher Poole, et al.
Clinical Medicine (London, England)|July 26, 2020
Characteristics and outcomes of patients with COVID-19 at a district general hospital in Surrey, UKHarry Knights, Nikhil Mayor, Kristina Millar, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Diabetes, Obesity & Metabolism|June 3, 2017
Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK settingDavid Russell-Jones, Simon R Heller, Sarah Buchs, et al.
BJU International|September 22, 2011
A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapyJenny P Nobes, Stephen E M Langley, Tanya Klopper, et al.
Diabetes|January 31, 2006
Contrasting insulin sensitivity of endogenous glucose production rate in subjects with hepatocyte nuclear factor-1beta and -1alpha mutationsAnna Brackenridge, Ewan R Pearson, Fariba Shojaee-Moradie, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trialsBernard Zinman, J Hans DeVries, Bruce Bode, et al.
Diabetes, Obesity & Metabolism|January 10, 2018
Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trialChantal Mathieu, Bruce W Bode, Edward Franek, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|November 9, 2024
The practical operation and consequences of glucose measurement by pilots with diabetesKa Siu Fan, Antonios Manoli, Fariba Shojaee-Moradie, et al.
Diabetes, Obesity & Metabolism|October 7, 2021
Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trialMelanie J Davies, Julio Rosenstock, Amar Ali, et al.
Diabetes Care|January 3, 2012
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind studyDavid Russell-Jones, Robert M Cuddihy, Markolf Hanefeld, et al.
Advances in Therapy|August 25, 2011
Insulin therapy in diabetes and cancer risk: current understanding and implications for future study: proceedings from a meeting of a European Insulin Safety Consensus Panel, convened and sponsored by Novo Nordisk, held Tuesday October 5, 2010 at The Radisson Edwardian Heathrow Hotel, Hayes, Middlesex, UKStephen C L Gough, Cristóbal Belda-Iniesta, Christopher Poole, et al.
Clinical Medicine (London, England)|July 26, 2020
Characteristics and outcomes of patients with COVID-19 at a district general hospital in Surrey, UKHarry Knights, Nikhil Mayor, Kristina Millar, et al.
Pageof 6